ENGLEWOOD, CO / ACCESSWIRE / December 5, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS® will be featured in a Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine held December 5-7, 2019 in Leipzig, Germany.
During the symposium, multiple clinical presentations featuring the MiOXSYS System will be made Friday, December 6, 2019 by leading andrologists and reproductive medicine experts from around the world. Professor Christian Schuppe, Professor and Chair of Urology at the University of Giessen, will chair the symposium.
The Product Symposium will be conducted at 10:30 AM CET at the Kongreshalle am Zoo Leipzig, Schiller Room.
Symposium Presenters & Presentations:
Moderator: Professor Dr. med. Hans-Christian Schuppe
Clinic and Policlinic for Urology, Pediatric Urology and Andrology
University Hospital Giessen und Marburg (UKGM) - Giessen
Oxidative Stress in Semen: Causes, Diagnosis and Significance for Assisted Reproduction
Presenter: Professor Dr. Ralf Henkel, PhD.
Department of Medical Bioscience
University of the Western Cape
Bellville, South Africa
Sperm in Danger: Oxidative Stress and Inflammation
Presenter: Professor Dr. med. Jean-Pierre Allam
Clinic and Policlinic for of Dermatology and Allergy
University Hospital Bonn (UKB)
The MiOXSYS System is currently in use in over thirty countries around the world and is CE Marked and cleared by Health Canada, the Australian Therapeutic Goods Administration (TGA), and Mexico's COFEPRAS.
Hosting of this Product Showcase does not imply endorsement of the MiOXSYS System by German Federation of Reproductive Biology and Medicine Congress.
About Aytu BioScience, Inc.
Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the effects of the business combination of Aytu and the Commercial Portfolio and the previously announced, but not yet consummated, merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, the failure to obtain the required votes of Innovus' shareholders or Aytu's shareholders to approve the Merger and related matters, the risk that a condition to closing of the Merger may not be satisfied, that either party may terminate the merger agreement or that the closing of the Merger might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration in the Merger may not be reflective of the current market price of Aytu's common stock on the closing date, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Investors:
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com: